MapLight Therapeutics, Inc. (MPLT)

Market Cap	1.33B
Revenue (ttm)	n/a
Net Income	-199.48M
EPS	-10.07
Shares Out	45.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	436,845
Open	29.56
Previous Close	29.78
Day's Range	29.12 - 30.69
52-Week Range	12.24 - 33.28
Beta	n/a
Analysts	Strong Buy
Price Target	37.90 (+29.31%)
Earnings Date	May 14, 2026

About MPLT

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; ML-055 for the treatment of neuropsychiatric co...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 27, 2025
• Employees: 133
• Stock Exchange: NASDAQ
• Ticker Symbol: MPLT
• Website: https://www.maplightrx.com

Analyst Summary

According to 11 analysts, the average rating for MPLT stock is "Strong Buy." The 12-month stock price target is $37.9, which is an increase of 29.31% from the latest price.

Price Target

$37.9

(29.31% upside)

Analyst Consensus: Strong Buy